Relevant bibliographies by topics / Ovarian cancer, chemotherapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Ovarian cancer, chemotherapy'

Author: Grafiati
Published: 24 April 2022
Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ovarian cancer, chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ovarian cancer, chemotherapy"

1

Christian, J., and H. Thomas. "Ovarian cancer chemotherapy." Cancer Treatment Reviews 27, no. 2 (2001): 99–109. http://dx.doi.org/10.1053/ctrv.2001.0219.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Friedrich, Michael, Alexander Khudyakov, Arne Terjung, Wolfgang Zinn, and Ulrich Füllers. "Influence of hyperthermic intraperitoneal chemotherapy (HIPEC) on the onset of adjuvant chemotherapy in ovarian cancer." Voprosy ginekologii, akušerstva i perinatologii 21, no. 2 (2022): 14–17. http://dx.doi.org/10.20953/1726-1678-2022-2-14-17.

Full text
Abstract:
Objective. To determine the benefits of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced ovarian cancer. Patients and methods. The study included 87 patients, while 74 patients had epithelial ovarian cancer and 13 patients showed other neoplasms. At the end of the operation, a 1-hour perfusion of the abdominal cavity was performed with cisplatin 50 mg/m2 at a temperature of 41°C. The patient data was retrospectively analyzed considering the time interval of postoperative chemotherapy based on the guideline. Results. Sixty patients manifested macrosc
APA, Harvard, Vancouver, ISO, and other styles
3

Mayomba, Colman, Godfrey Kaizilege, Richard Kiritta, et al. "Metachronous Ovarian Cancer after a Radical Hysterectomy with Ovarian Conservation for Early-Stage Cervical Cancer: A Case Report." International Journal of Medical Case Reports and Reviews 2, no. 4 (2023): 1–5. http://dx.doi.org/10.59657/2837-8172.brs.23.023.

Full text
Abstract:
Introduction: Cervical cancer is the fourth most common disease in women worldwide and the leading cause in Tanzania, with 9,772 new cases and 6,695 deaths annually. Surgery is better than radiation or chemotherapy for early-stage cervical cancer (stages IA2–IIA1). Due to the risks of oophorectomy in young women, ovarian conservation is crucial. Metachronous ovarian cancer is understudied, however, ovarian conservation does not enhance cervical cancer mortality. Clinical presentation: We report a rare case of recurrent metachronous ovarian cancer in a 42-year-old female, Para 3, Living 3, who
APA, Harvard, Vancouver, ISO, and other styles
4

OCHIAI, Kazunori. "Chemotherapy for Ovarian Cancer." Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) 29, no. 4 (2004): 685–89. http://dx.doi.org/10.4030/jjcs1979.29.4_685.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lim, Myong Cheol, and Sang-Yoon Park. "Chemotherapy for ovarian cancer." Journal of the Korean Medical Association 59, no. 3 (2016): 175. http://dx.doi.org/10.5124/jkma.2016.59.3.175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kaye, S. B. "Chemotherapy for ovarian cancer." European Journal of Cancer 29, no. 4 (1993): 632–35. http://dx.doi.org/10.1016/s0959-8049(05)80168-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gamal, Abdul Hamid, Saleh Hadi Amani, and Ali Yeslam Nadia. "Ovarian cancer in southeastern of Yemen." GSC Advanced Research and Reviews 10, no. 3 (2022): 047–51. https://doi.org/10.5281/zenodo.6401099.

Full text
Abstract:
<strong>Introduction:&nbsp;</strong>Ovarian cancer is an important cause of mortality in women. The incidence of ovarian cancer and survival rates are still relatively unknown in southeast Yemen. This study takes into account trends in ovarian cancer incidence and survival rates by examining age, histological subtypes, residency, and treatment. <strong>Methods:</strong>&nbsp;The National Cancer Center Aden is the premier cancer care transformation center in the southeastern governorates and the source for collecting data on ovarian cancer mortality from 2014-2020 from the Surveillance, Epidemi
APA, Harvard, Vancouver, ISO, and other styles
8

Lowe, Thomas, and Robert J. Morgan. "Intraperitoneal Chemotherapy of Ovarian Cancer." Women's Health 3, no. 4 (2007): 433–40. http://dx.doi.org/10.2217/17455057.3.4.433.

Full text
Abstract:
Ovarian cancer is the leading cause of death among cancers of the female reproductive tract. Most women present with regionally advanced intraperitoneal disease with superficial spread of tumor along the peritoneal surfaces. Distant metastasis rarely occurs until late in the disease process; however, long-term survival of patients with advanced disease remains poor. Intraperitoneal chemotherapy allows higher concentration and prolonged half-life of chemotherapy within the peritoneal cavity compared with intravenous administration, while therapeutic intravenous concentrations are obtained. Thre
APA, Harvard, Vancouver, ISO, and other styles
9

Dressman, Holly K., Andrew Berchuck, Gina Chan, et al. "An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer." Journal of Clinical Oncology 25, no. 5 (2007): 517–25. http://dx.doi.org/10.1200/jco.2006.06.3743.

Full text
Abstract:
Purpose The purpose of this study was to develop an integrated genomic-based approach to personalized treatment of patients with advanced-stage ovarian cancer. We have used gene expression profiles to identify patients likely to be resistant to primary platinum-based chemotherapy and also to identify alternate targeted therapeutic options for patients with de novo platinum-resistant disease. Patients and Methods A gene expression model that predicts response to platinum-based therapy was developed using a training set of 83 advanced-stage serous ovarian cancers and tested on a 36-sample extern
APA, Harvard, Vancouver, ISO, and other styles
10

Dood, Robert, Nicole D. Fleming, Robert L. Coleman, Shannon Neville Westin, and Anil Sood. "When advanced ovarian cancer is not ovarian cancer." Journal of Clinical Oncology 35, no. 15_suppl (2017): e17066-e17066. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e17066.

Full text
Abstract:
e17066 Background:Tissue diagnosis of advanced ovarian cancer (OC) is not universally obtained prior to up-front surgery. This study sought to investigate non-OC cases discovered in the systemic laparoscopic (LSC) workup of presumed advanced OC. Methods: A prospective cohort of presumed advanced OC patients (based on elevated CA125 and/or imaging) presenting to our center without confirmed pathologic diagnosis. Patients with non-OC pathology confirmed in workup were characterized and compared to those with confirmed ovarian pathology using standard statistical tests. Results: 365 patients pres
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Ovarian cancer, chemotherapy"

1

Newton, C. "Clinical resistance to platinum chemotherapy in ovarian cancer." Thesis, University College London (University of London), 2009. http://discovery.ucl.ac.uk/1446312/.

Full text
Abstract:
Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results from DNA crosslinking. High tumour response rates are seen, but 80 % of patients relapse. Major mechanisms of platinum resistance in patients remain to be established. We have studied DNA interstrand crosslinking and its repair in response to ex vivo treatment with cisplatin in forty patients with ovarian cancer using the single cell gel electrophoresis (comet) assay. Tumour cells from resected tumours or tumour and mesothelial cells from ascites were obtained from chemonaive patients and those relapsing aft
APA, Harvard, Vancouver, ISO, and other styles
2

Gao, Bo. "Genetic polymorphisms and chemotherapy response in ovarian cancer." Thesis, The University of Sydney, 2014. http://hdl.handle.net/2123/12884.

Full text
Abstract:
Epithelial ovarian cancer (EOC) is usually treated with paclitaxel and carboplatin combination. Germline genetic variations may affect drug clearance therefore response. ABCB1 (ATP-binding cassette B1) is an efflux transporter of paclitaxel. We found an association between ABCB1 polymorphisms and survival in EOC patients. In lymphoblastoid cell lines (LCLs), ABCB1 expression correlated with transporter activity and paclitaxel sensitivity, but not with ABCB1 polymorphisms. In a prospective pharmacokinetic study, an association was identified between ABCB1 genotypes and paclitaxel clearance in t
APA, Harvard, Vancouver, ISO, and other styles
3

Shirai, Takako. "Primary chemotherapy patterns for ovarian cancer treatment in Japan." Kyoto University, 2010. http://hdl.handle.net/2433/120581.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kikkawa, Fumitaka, Akihiro Nawa, Kazuhiko Ino, et al. "Advances in treatment of epithelial ovarian cancer." Nagoya University School of Medicine, 2006. http://hdl.handle.net/2237/6129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lo, Charlotte Sum-Yee. "Immune infiltration in ovarian cancer and its significance in chemotherapy." Thesis, University of British Columbia, 2015. http://hdl.handle.net/2429/52275.

Full text
Abstract:
High grade serous carcinoma (HGSC), the most commonly diagnosed ovarian cancer subtype, is often presented as late stage disease with high recurrence rates, thus contributing to poor prognosis. Despite poor survival outcomes, the presence of tumour-infiltrating lymphocytes (TIL) in primary, untreated tumours is associated with increased survival. However, little is known about the phenotype and composition of TIL subsets in HGSC patients following treatment. In this thesis, we investigated the functional phenotype of TIL and the changes in immune composition in tumours over the course of ch
APA, Harvard, Vancouver, ISO, and other styles
6

Bolyard, Chelsea M. "Oncolytic Virus Therapy in Combination with Chemotherapy for Ovarian Cancer." The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1386007453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chowdhury, Mohd Raquibul. "Ovarian Cancer therapy combining the modalities of hyperthermia and chemotherapy." FIU Digital Commons, 2007. https://digitalcommons.fiu.edu/etd/2351.

Full text
Abstract:
Ovarian is the leading cause of deaths in women diagnosed with gynecological malignancies. Current treatments include chemotherapy which may cause severe side effects. The purpose of this study was to investigate the combinational therapeutic effect of chemotherapy and hyperthermia to an ovarian cancer cell line and compare the effects of inducing hyperthermia systemically with localized hyperthermia. Cells were seeded in 96-well plates and subjected to different doses of chemotherapy agent; Doxorubicin (DOX). To simulate systemic hyperthermia the 96-well plate was incubated for 60 minutes at
APA, Harvard, Vancouver, ISO, and other styles
8

Österberg, Lovisa. "Characterization of genetic alterations in ovarian cancer associated with chemotherapy response /." Göteborg : Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, 2009. http://hdl.handle.net/2077/20291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Abo, Donia Mohammed Najim Abed. "Evaluation of drug combinations to sensitize ovarian cancer cells to chemotherapy." Thesis, Keele University, 2018. http://eprints.keele.ac.uk/4591/.

Full text
Abstract:
Ovarian cancer is a complex disease characterized by low incidence, accounting for about 4% of cancer diagnoses in women, but with rapid progression and higher mortality rate than any other gynecological malignancy. Approximately 70 % of the cases are diagnosed late in the course of the disease due to unawareness of subtle symptoms and failure of screening methods for detecting the disease at early-stage. Although most patients respond well to standard treatment, which involves surgery followed by platinum/taxane combination therapy, relapse seems unavoidable and the majority of patients prese
APA, Harvard, Vancouver, ISO, and other styles
10

Singh, K. J. D. L. "Ovarian reserve testing in premenopausal recipients of chemotherapy for breast cancer." Thesis, University College London (University of London), 2008. http://discovery.ucl.ac.uk/1444394/.

Full text
Abstract:
The incidence of breast cancer has progressively increased, while survival rates have simultaneously improved. Young women with breast cancer are likely to suffer ovarian damage from chemotherapy, which can have a profound effect on their quality of life. At present, it is impossible to predict the functional lifespan of the chemotherapeutically damaged ovary as there is insufficient data. Ovarian reserve tests (ORT) have the potential to estimate the reproductive age of the ovaries, which would allow an accurate estimation of fertility status and the risk of premature ovarian failure. This pr
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Ovarian cancer, chemotherapy"

1

Hess, Lisa M., David S. Alberts, and Mary C. Clouser. Intraperitoneal therapy for ovarian cancer. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hyde, Susan Sturges. No more bad-hair days: A woman's journey through cancer, chemotherapy, and coping. Longstreet Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Excellence, National Institute for Clinical. Guidance on the use of paclitaxel in the treatment of ovarian cancer. National Institute for Clinical Excellence, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Graser, Angeline. Letters along my journey: My experience with cancer and chemotherapy. AuthorHouse, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

R, Lamonte Jean, ed. Aromatase inhibitors: Types, mode of action, and indications. Nova Science Publishers, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

R, Lamonte Jean, ed. Aromatase inhibitors: Types, mode of action, and indications. Nova Science Publishers, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

R, Lamonte Jean, ed. Aromatase inhibitors: Types, mode of action and indications. Nova Biomedical Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ozols, Robert F. High-dose Platinol (cisplatin for infection) in hypertonic saline. Bristol-Myers Oncology Division, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lamonte, Jean R. Aromatase inhibitors: Types, mode of action and indications. Nova Biomedical Books, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Malmström, Henric. Intraperitoneal chemotherapy of ovarian cancer. Linköping University, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Ovarian cancer, chemotherapy"

1

Guthrie, D. "Chemotherapy in Multicentre Studies." In Ovarian Cancer. Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69695-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wiltshaw, E. "Chemotherapy in a Single Centre." In Ovarian Cancer. Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69695-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gray, Heidi J. "Ovarian Cancer Chemotherapy." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_6972-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gray, Heidi J. "Ovarian Cancer Chemotherapy." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_6972.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gray, Heidi J. "Ovarian Cancer Chemotherapy." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_6972.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Newlands, E. S., R. H. J. Begent, G. J. S. Rustin, L. Holden, and K. D. Bagshawe. "Chemotherapy for Malignant Ovarian Germ Cell Tumours." In Ovarian Cancer. Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-69695-4_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Barber, Hugh R. K. "Role of Chemotherapy in Ovarian Cancer." In Ovarian Carcinoma. Springer New York, 1993. http://dx.doi.org/10.1007/978-1-4613-9232-3_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ozols, Robert F. "Chemotherapy of ovarian cancer." In Gynecologic Oncology. Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5447-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tew, William P. "Ovarian Cancer: Primary Chemotherapy." In Management of Gynecological Cancers in Older Women. Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-4605-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Elkas, John C., Oliver Dorigo, and Jonathan S. Berek. "Intraperitoneal Biologic Therapy for Ovarian Cancer." In Regional Chemotherapy. Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-219-7_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ovarian cancer, chemotherapy"

1

Chaudhary, Sushila. "Successful pregnancy outcome in recurrent ovarian cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685320.

Full text
Abstract:
Incidences of ovarian cancer in pregnancy are increasing nowadays due to routine use of ultrasonography in first trimester and postponement of childbirth to an older age. Reported incidence of ovarian tumor in pregnancy is 1:1000 among them3.6% are malignant. We report a case of recurrent ovarian tumor with successful pregnancy outcome. She was a 26 yr old primi had ovarian cancer recurrence 2 year after primary surgery. In present pregnancy she was given chemotherapy with two doses of carboplatin, and had viable baby at 34 weeks of pregnancy. At present mother and baby are doing well and on r
APA, Harvard, Vancouver, ISO, and other styles
2

Nakka, Thejeswar, Prasanth Ganesan, Luxitaa Goenka, et al. "Epithelial Ovarian Cancer: Real-World Outcomes." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735369.

Full text
Abstract:
Abstract Introduction Ovarian cancer is the third most common cancer and the second most common cause of death among gynecological cancers in Indian women. Ovarian cancer is heterogeneous, among them, epithelial ovarian cancer (EOC) is the most common. Primary cytoreductive surgery along with six to eight cycles of a combination of platinum and taxanes chemotherapy is the cornerstone of first-line treatment in EOC. This study was done to find clinicopathological factors affecting survival outcomes with first-line therapy in EOC in a real-world setting. Objectives This study was aimed to find f
APA, Harvard, Vancouver, ISO, and other styles
3

Therasakvichya, Suwanit, and Siree Limtiamchareon. "Ambulatory chemotherapy in epithelial ovarian cancer patients." In The 7th Biennial Meeting of Asian Society of Gynecologic Oncology. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology, 2021. http://dx.doi.org/10.3802/jgo.2021.32.s1.o28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lisboa, Elis Nogara, Rita de Cassia Lima, Leticia Taniwaki, et al. "DELETERIOUS VARIANTS IN RAD51C GENE AND BREAST CANCER – REPORT OF THREE PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2074.

Full text
Abstract:
RAD51C is a gene associated with hereditary predisposition to ovarian cancer, and its association with hereditary breast cancer was controversial for a while. Current evidence demonstrates that RAD51C deleterious variants increase the risk of estrogen receptor-negative breast cancer. This study presents three unrelated patients with triple-negative breast tumors with heterozygous deleterious RAD51C variants. The first patient was diagnosed with post-menopausal breast cancer at 55 years of age and treated with conservative surgery and adjuvant chemotherapy. Her sister had breast cancer at 49 ye
APA, Harvard, Vancouver, ISO, and other styles
5

Li, Yan-E., Juan Zhang, Bin Han, and Lihua Li. "Identifying Ovarian Cancer Chemotherapy Response Relevant Gene Cliques." In 2011 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2011. http://dx.doi.org/10.1109/bibm.2011.65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Salvai, M., RM Riege, J. Costa, G. Santillan, and M. Rosso. "329 Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer." In IGCS Annual 2019 Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-igcs.329.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685313.

Full text
Abstract:
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated
APA, Harvard, Vancouver, ISO, and other styles
8

Shah, Swati, Shveta Giri, Rupinder Sekhon, and Sudhir Rawal. "Inguinal lymphadenopathy as a presentation for ovarian cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685329.

Full text
Abstract:
Ovarian carcinoma usually presents at an advanced stage with diffuse intra abdominal manifestations. Inguinal lymph node metastasis is rare event in ovarian cancer. We report 7 cases who presented with inguinal lymphadenopathy as the initial manifestation between January 2014 to January 2016. All patients underwent tru-cut biopsy from inguinal area. Morphology and IHC were suggestive of ovarian origin or female genital Tract origin. Two patients underwent primary debulking surgery while four patients were managed by neo-adjuvant chemotherapy followed by interval cytoreductive surgery owing to
APA, Harvard, Vancouver, ISO, and other styles
9

Kumar, Siva. "Neoadjuvant chemotherapy in epithelial ovarian cancer: Largest single institute experience." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685312.

Full text
Abstract:
Purpose: Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is an alternative treatment option, compared to the current standard of care primary debulking surgery for treating advanced epithelial ovarian cancer (EOC). We present our institute experience of neoadjuvant chemotherapy strategy in the management of EOC which is one of the largest single institute experience. Methods: This is a retrospective analysis of patients with epithelial ovarian cancer who were treated in our institute between 2000 and 2006. Patient with advanced disease by clinical and imaging were treated
APA, Harvard, Vancouver, ISO, and other styles
10

Ghuge, Dhananjay, Alok Tiwari, Subraharsh Singh, and Satinder Kaur. "Clinico-pathological characterstics of epithelial ovarian malignancy in young female." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685298.

Full text
Abstract:
Background and Objective: Epithelial ovarian cancer mostly appears in aged women, but rarely in young women. Little is known about the clinical characteristics and prognosis of epithelial ovarian cancer in women aged below 40 years. This study was to evaluate the clinical and histopathological characteristics of young patients with epithelial ovarian cancer. Methods: A total of 31 patients with confirmed epithelial ovarian cancer under the age of 40 years between 2007 to 2015 were retrospectively analyzed. Results: Mean age of the patient is 32 years. The common symptoms included abdominal pai
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Ovarian cancer, chemotherapy"

1

Kengsakul, Malika, Gatske Nieuwenhuyzen – de Boer, and Heleen van Beekhuizen. Radiological factors associated with residual disease after cytoreductive surgery for advanced ovarian cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.1.0059.

Full text
Abstract:
Review question / Objective: Which radiological factors associated with incomplete cytoreduction (gross residual disease) after cytoreductive surgery (CRS) for advanced ovarian cancer? Condition being studied: Findings of CT scan and discussion in the multidisciplinary tumor board meeting (MDO) are crucial to determine the therapeutic strategy for individual ovarian cancer patients. Preferably, patients undergo primary cytoreductive surgery (CRS) followed by adjuvant chemotherapy. However, when complete cytoreduction is not considered feasible, neoadjuvant chemotherapy followed by interval cyt
APA, Harvard, Vancouver, ISO, and other styles
2

Guo, Jing, Yu han Chen, Chun xiao Li, et al. Meta-analysis of Kangai injection combined with radiotherapy and chemotherapy in the treatment of gynecological malignant tumors. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0063.

Full text
Abstract:
Review question / Objective: This study systematically evaluated the clinical efficacy and safety of Kangai injection combined with radiotherapy and chemotherapy in the treatment of gynecological malignant tumors. The subjects of the study were patients with clinical diagnosis of ovarian cancer, cervical cancer, and endometrial cancer. The experimental group was given Kang'ai injection combined with radiotherapy and chemotherapy, while the control group was given conventional chemotherapy. The primary outcome was the overall clinical response rate. Secondary outcomes included quality of life,
APA, Harvard, Vancouver, ISO, and other styles
3

Wang, Yan. For platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction combined with intravenous chemotherapy versus chemotherapy alone. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.7.0063.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lieber, Andre. A Combination Therapy of JO-1 and Chemotherapy in Ovarian Cancer Models. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada613643.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lieber, Andre. A Combination Therapy of JO-I and Chemotherapy in Ovarian Cancer Models. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada598401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Frost, Marlene H., Charles Loprinzi, Ann Kearns, Jeff Sloan, and Debra Barton. Changes in Ovarian Stromal Function in Premenopausal Women Undergoing Chemotherapy for Breast Cancer. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada446278.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Barton, Debra, Jeff Sloan, Charles Loprinzi, and Ann Kearns. Changes in Ovarian Stromal Function in Premenopausal Women Undergoing Chemotherapy for Breast Cancer. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada428981.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Chien, Jeremy. Integrative Functional Genomics and Proteomics to Uncover Mechanisms of Resistance to Chemotherapy in Ovarian Cancer. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada548144.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Frost, Marlene H. Changes in Ovarian Stromal Function and Associated Symptoms in Premenopausal Women Undergoing Chemotherapy for Breast Cancer. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada510068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wenzel, Lari, Dana Mukamel, and Kathryn Osann. Testing a Decision Aid to Help Patients with Ovarian Cancer Choose between Two Ways to Get Chemotherapy. Patient-Centered Outcomes Research Institute (PCORI), 2020. http://dx.doi.org/10.25302/07.2020.ce.12114755.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ovarian cancer, chemotherapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography